Posted inNews and Updates
AI-Designed IPF Drug Rentosertib Enters Phase III Trials
Insilico Medicine’s AI-discovered drug, Rentosertib, enters Phase III trials for IPF. A breakthrough in AI-driven drug development for lung fibrosis.
Posted inNews and Updates
Seegene Launches Global Million-Patient Clinical Study
Seegene launches a landmark one-million-patient global study to set new international standards for molecular diagnostic testing and syndromic accuracy.
Posted inNews and Updates
HHS Launches Initiative to Improve Hospital Food Nutrition
HHS launches a new national pledge to improve hospital food quality, prioritizing patient nutrition to support recovery and reduce chronic disease outcomes.
Posted inNews and Updates
XIAFLEX Shows Promise in Phase 3 Trial for Plantar Fibromatosis
New Phase 3 data reveals that XIAFLEX significantly improves symptoms of plantar fibromatosis, offering a potential non-surgical breakthrough for patients.
Posted inNews and Updates
FDA Provides Positive Guidance to OKYO Pharma on Drug Trial
OKYO Pharma receives positive FDA feedback on its lead ocular candidate, OK-101. Learn how this regulatory milestone impacts the future of dry eye treatment.
Posted inNews and Updates
Turn Therapeutics Stock Rises on Positive AD Trial Data
Turn Therapeutics stock surges after promising AD clinical trial results. Learn how the company is expanding its pipeline to tackle chronic skin conditions.
Posted inNews and Updates
Theriva Secures Spanish Approval for VCN-01 Pancreatic Trial
Theriva Biologics gains Spanish approval for Phase 2a trials of VCN-01. Learn how this novel oncolytic virus targets treatment-resistant pancreatic cancer.
Posted inNews and Updates
Agios Receives Priority Review for Sickle Cell Drug Mitapivat
The FDA has granted Priority Review to Agios Pharmaceuticals’ mitapivat for Sickle Cell Disease. Learn how this PK activator could transform SCD treatment.
Posted inNews and Updates
FDA Approves Accelerated Phase 3 Pathway for MSA Drug ATH434
The FDA has greenlit a single Phase 3 trial for ATH434, potentially accelerating the approval process for a new Multiple System Atrophy treatment.
Posted inNews and Updates
EMA Grants Accelerated Review for Daraxonrasib in Pancreatic Cancer
The EMA has fast-tracked the review of daraxonrasib for metastatic pancreatic cancer, potentially offering new hope for treatment-resistant patients.